These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 3106810)

  • 1. Increased concentrations of cholestanol and apolipoprotein B in the cerebrospinal fluid of patients with cerebrotendinous xanthomatosis. Effect of chenodeoxycholic acid.
    Salen G; Berginer V; Shore V; Horak I; Horak E; Tint GS; Shefer S
    N Engl J Med; 1987 May; 316(20):1233-8. PubMed ID: 3106810
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Cerebrotendinous xanthomatosis: long-term treatment with chenodesoxycholic acid (author's transl)].
    Wolf LM; Houdent C; Laudat MH; Brasseur G; Balacheff O; Uzac L
    Nouv Presse Med; 1982 Mar; 11(11):855-7. PubMed ID: 7070978
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of cerebrotendinous xanthomatosis with chenodeoxycholic acid.
    Pedley TA; Emerson RG; Warner CL; Rowland LP; Salen G
    Ann Neurol; 1985 Oct; 18(4):517-8. PubMed ID: 4073846
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Isotopomer spectral analysis of intermediates of cholesterol synthesis in patients with cerebrotendinous xanthomatosis.
    Clarenbach JJ; Lindenthal B; Dotti MT; Federico A; Kelleher JK; von Bergmann K
    Metabolism; 2005 Mar; 54(3):335-44. PubMed ID: 15736111
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transformation of 4-cholesten-3-one and 7 alpha-hydroxy-4-cholesten-3-one into cholestanol and bile acids in cerebrotendinous xanthomatosis.
    Salen G; Shefer S; Tint GS
    Gastroenterology; 1984 Aug; 87(2):276-83. PubMed ID: 6735073
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Cerebrotendinous xanthomatosis].
    Berginer VM
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1992; 92(4):13-22. PubMed ID: 1333699
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Capillary gas chromatographic determination of cholestanol/cholesterol ratio in biological fluids. Its potential usefulness for the follow-up of some liver diseases and its lack of specificity in diagnosing CTX (cerebrotendinous xanthomatosis).
    Koopman BJ; van der Molen JC; Wolthers BG; de Jager AE; Waterreus RJ; Gips CH
    Clin Chim Acta; 1984 Mar; 137(3):305-15. PubMed ID: 6421514
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Normalisation of serum cholestanol concentration in a patient with cerebrotendinous xanthomatosis by combined treatment with chenodeoxycholic acid, simvastatin and LDL apheresis.
    Dotti MT; Lütjohann D; von Bergmann K; Federico A
    Neurol Sci; 2004 Oct; 25(4):185-91. PubMed ID: 15549503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High levels of plant sterols and cholesterol precursors in cerebrotendinous xanthomatosis.
    Kuriyama M; Fujiyama J; Kasama T; Osame M
    J Lipid Res; 1991 Feb; 32(2):223-9. PubMed ID: 2066659
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative effects of lovastatin and chenodeoxycholic acid on plasma cholestanol levels and abnormal bile acid metabolism in cerebrotendinous xanthomatosis.
    Salen G; Batta AK; Tint GS; Shefer S
    Metabolism; 1994 Aug; 43(8):1018-22. PubMed ID: 8052141
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of cerebrotendinous xanthomatosis: effects of chenodeoxycholic acid, pravastatin, and combined use.
    Kuriyama M; Tokimura Y; Fujiyama J; Utatsu Y; Osame M
    J Neurol Sci; 1994 Aug; 125(1):22-8. PubMed ID: 7964884
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined treatment with chenodeoxycholic acid and pravastatin improves plasma cholestanol levels associated with marked regression of tendon xanthomas in cerebrotendinous xanthomatosis.
    Nakamura T; Matsuzawa Y; Takemura K; Kubo M; Miki H; Tarui S
    Metabolism; 1991 Jul; 40(7):741-6. PubMed ID: 1908036
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of cerebrotendinous xanthomatosis with chenodeoxycholic acid in three siblings.
    Chang WN; Kuriyama M; Chee EC
    J Formos Med Assoc; 1994 Mar; 93(3):256-9. PubMed ID: 7920069
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term treatment of cerebrotendinous xanthomatosis with chenodeoxycholic acid.
    Berginer VM; Salen G; Shefer S
    N Engl J Med; 1984 Dec; 311(26):1649-52. PubMed ID: 6504105
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Cerebrotendinous xanthomatosis].
    Burghaus L; Liu W; Haupt WF
    Dtsch Med Wochenschr; 2007 Jul; 132(27):1463-6. PubMed ID: 17583829
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Laboratory diagnosis of a rare congenital neurodegenerative disease: cerebrotendinous xanthomatosis].
    Varga VE; Katkó M; Harangi J; Balogh I; Kapás I; Madar L; Seres I; Molnár MJ; Paragh G; Kovács GG; Harangi M
    Orv Hetil; 2014 May; 155(21):811-6. PubMed ID: 24836315
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low-density lipoprotein metabolism in cerebrotendinous xanthomatosis.
    Ballantyne CM; Vega GL; East C; Richards G; Grundy SM
    Metabolism; 1987 Mar; 36(3):270-6. PubMed ID: 3821507
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The metabolism of cholestanol, cholesterol, and bile acids in cerebrotendinous xanthomatosis.
    Salen G; Grundy SM
    J Clin Invest; 1973 Nov; 52(11):2822-35. PubMed ID: 4355999
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chronic diarrhea and juvenile cataracts: think cerebrotendinous xanthomatosis and treat.
    Berginer VM; Gross B; Morad K; Kfir N; Morkos S; Aaref S; Falik-Zaccai TC
    Pediatrics; 2009 Jan; 123(1):143-7. PubMed ID: 19117873
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chenodeoxycholic acid normalizes elevated lipoprotein secretion and catabolism in cerebrotendinous xanthomatosis.
    Tint GS; Ginsberg H; Salen G; Le NA; Shefer S
    J Lipid Res; 1989 May; 30(5):633-40. PubMed ID: 2760539
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.